Inter-individual variability in drug response, be it efficacy or safety, is common and likely to
become an increasing problem globally given the growing elderly population requiring …

The objective of this study was to evaluate the evidence on cost‐effectiveness of
pharmacogenetic (PGx)–guided treatment for drugs with Clinical Pharmacogenetics …

Pharmacogenetics (PGx) has the potential to personalize pharmaceutical treatments. Many
relevant gene–drug associations have been discovered, but PGx-guided treatment needs to …

Phenytoin is a widely used antiepileptic drug with a narrow therapeutic index and large
interpatient variability, partly due to genetic variations in the gene encoding cytochrome …

Abstract HLA-A* 31: 01 was reported to be associated with carbamazepine (CBZ)-induced
severe cutaneous adverse reactions (SCAR), including drug reaction with eosinophilia and …

Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a life-threatening,
immunologically mediated, and usually drug-induced disease with a high burden to …

Human leukocyte antigen (HLA) encoded by the HLA gene is an important modulator for
immune responses and drug hypersensitivity reactions as well. Genetic polymorphisms of …

Background Pharmacogenetics offers the potential to improve health outcomes by
identifying individuals who are at greater risk of harm from certain medicines. Routine …

Individuals differ substantially in their response to pharmacological treatment. Personalized
medicine aspires to embrace these inter-individual differences and customize therapy by …

Objective: To investigate the risk and genetic association of oxcarbazepine-induced
cutaneous adverse reactions (OXC-cADRs), including Stevens-Johnson syndrome/toxic …